JAK2 V617F, the most prevalent mutation in cMPNs, is detected in over 95% of polycythemia vera (PV) cases and approximately 50–60% of essential thrombocythemia (ET) and primary myelofibrosis (PMF) cases. The gene discussed is JAK2; the disease is acquired polycythemia vera.